Does Cymbalta Relieve Nerve Pain?
Cymbalta (duloxetine), a serotonin-norepinephrine reuptake inhibitor (SNRI), is FDA-approved for diabetic peripheral neuropathic pain in adults. It reduces pain signals in the brain and spinal cord by boosting serotonin and norepinephrine levels.[1] Clinical trials showed about 50% of patients with diabetic neuropathy experienced at least 30% pain reduction after 12-13 weeks, compared to 30% on placebo.[2]
How Effective Is It for Different Types of Nerve Pain?
- Diabetic neuropathy: Strong evidence from randomized trials; approved dose is 60 mg daily.[1]
- Chemotherapy-induced: Effective in some studies, reducing pain by 50-60% in breast cancer patients.[3]
- Other neuropathies (e.g., postherpetic neuralgia, sciatica): Used off-label with moderate success; meta-analyses report 40-50% response rates, similar to pregabalin or gabapentin.[4]
Pain relief typically starts in 1-4 weeks, peaks at 4-6 weeks.
How Does Cymbalta Compare to Other Nerve Pain Treatments?
| Treatment | Effectiveness for Neuropathy | Common Dose | Key Differences |
|-----------|------------------------------|-------------|-----------------|
| Cymbalta | 50% moderate relief | 60 mg/day | Dual antidepressant + pain action; fewer cognitive side effects than opioids |
| Lyrica (pregabalin) | 45-50% relief | 300-600 mg/day | Faster onset (days); more dizziness/weight gain[4] |
| Gabapentin | 40-50% relief | 900-3600 mg/day | Cheaper generic; sedation common |
| Amitriptyline | 40-60% relief | 25-150 mg/night | Older tricyclic; more anticholinergic effects (dry mouth, constipation)[5] |
Cymbalta often edges out in long-term tolerability for patients with depression too.
What Side Effects Do Patients Report?
Most common: nausea (20-25%), dry mouth (15%), fatigue (10-15%), dizziness. Serious risks include liver damage (rare), serotonin syndrome, or suicidal thoughts (black box warning).[1] Withdrawal symptoms like electric shocks occur if stopped abruptly—taper over 2-4 weeks.
Who Should Avoid It and What Dosage Works Best?
Avoid in uncontrolled narrow-angle glaucoma, severe liver/kidney issues, or with MAOIs. Start at 30 mg/day, increase to 60 mg; max 120 mg. Elderly or low-weight patients need lower doses.[1] Not for kids under 18.
When Does It Lose Patent Protection?
Cymbalta's main patents expired in 2013; generics available since then, priced at $10-30/month vs. $400+ for brand.[6]
[1]: FDA Label - Cymbalta (https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021427s035lbl.pdf)
[2]: Lunn et al., Cochrane Review (2014) (https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006152.pub3/full)
[3]: Smith et al., JAMA (2013) (https://jamanetwork.com/journals/jama/fullarticle/1682819)
[4]: Quilici et al., Eur J Neurol (2009) (https://onlinelibrary.wiley.com/doi/10.1111/j.1468-1331.2008.02372.x)
[5]: Moore et al., Cochrane Review (2015) (https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007938.pub3/full)
[6]: DrugPatentWatch - Cymbalta (https://www.drugpatentwatch.com/p/tradename/CYMBALTA)